<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01434134</url>
  </required_header>
  <id_info>
    <org_study_id>2709001/90005</org_study_id>
    <nct_id>NCT01434134</nct_id>
  </id_info>
  <brief_title>Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy</brief_title>
  <acronym>PRADA</acronym>
  <official_title>Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: A Randomized, Placebo-controlled, 2x2 Factorial, Double Blind Trial of Candesartan and Metoprolol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Akershus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norwegian Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Akershus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Women treated for breast cancer are at increased risk for cardiovascular disease, including
      heart failure. In this study, by using magnetic resonance imaging (MRI), the investigators
      want to assess if heart failure medications such as beta blockers and angiotensin receptor
      blockers can prevent cardiac dysfunction during early breast cancer therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Breast cancer is one of the most common malignancies in women. Recent progress in the
      detection and treatment of breast cancer has resulted in survival gains, but a consequence of
      therapeutic advances is an increasing number of long-term survivors who may be at risk for
      development of cardiovascular disease. Several studies suggest that women treated for breast
      cancer may be at increased risk for cardiovascular disease, the probable causes being
      multi-factorial. Importantly, therapies for breast cancer, including radiotherapy, anti-HER-2
      regimens and certain chemotherapeutic regimens, may increase the risk of subsequent
      cardiovascular disease, including atherosclerotic disease, left ventricular dysfunction, and
      heart failure.

      In the current study we propose to undertake a randomized, placebo-controlled, 2x2 factorial,
      double-blind trial to assess whether left ventricular dysfunction and/or injury is
      preventable, completely or partly, by the concomitant administration of the angiotensin
      receptor blocker (ARB), candesartan, and the beta blocker, metoprolol, during postoperative
      chemotherapy and radiotherapy.

      The proposed study addresses an important clinical problem in a large patient group. Thus,
      the possibility of preventing cardiovascular side effects of contemporary therapy for breast
      cancer is important both clinically and scientifically.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in left ventricular ejection fraction, as assessed by cardiac MRI</measure>
    <time_frame>Baseline and end of study (up to 72 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in contrast enhancement by MRI</measure>
    <time_frame>Baseline and approximately 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in left 2D global strain, as assessed by echocardiography</measure>
    <time_frame>Baseline and end of study (up to 72 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinical of heart failure or objective left ventricular dysfunction</measure>
    <time_frame>Up to 72 weeks</time_frame>
    <description>Left ventricular dysfunction defined as ejection fraction &lt; 55% by cardiac MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in biochemical markers of cardiac injury, i.e. hs-cTnT</measure>
    <time_frame>Baseline and end of study (up to 72 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in left ventricular diastolic function, as assessed by echocardiography</measure>
    <time_frame>Baseline and end of study (up to 72 weeks)</time_frame>
    <description>Diastolic function assessed by e/e'</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in biochemical markers of cardiac function, i.e. NT-proBNP</measure>
    <time_frame>Baseline and end of study (up to 72 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in contrast enhancement, as assessed by cardiac MRI</measure>
    <time_frame>Baseline and end of study (up to 72 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Metoprolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablet, target dose 100 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for Metoprolol</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Tablet, target dose 100 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Candesartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablet, target dose 32 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for Candesartan</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Tablet, target dose 32 mg once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprolol</intervention_name>
    <description>Tablet, target dose 100 mg once daily</description>
    <arm_group_label>Metoprolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablet, target dose 100 mg once daily</description>
    <arm_group_label>Placebo for Metoprolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan</intervention_name>
    <description>Tablet, target dose 32 mg once daily</description>
    <arm_group_label>Candesartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablet, 32 mg once daily</description>
    <arm_group_label>Placebo for Candesartan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women aged 18-70 years

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          -  Serum creatinine &lt; 140 Î¼mol/L or estimated creatinine clearance &gt; 60 ml/min (using the
             modification of diet and renal disease (MDRD) formula)

          -  Systolic blood pressure &gt;= 110 mgHg and &lt; 170 mmHg

          -  LVEF &gt;= 50%

        Exclusion Criteria:

          -  Hypotension, defined as systolic blood pressure &lt; 110 mmHg

          -  Bradycardia, defined as heart rate &lt; 50 b.p.m.

          -  Prior anthracycline chemotherapy regimen

          -  Prior malignancy requiring chemotherapy or radiotherapy

          -  Symptomatic heart failure

          -  Systolic dysfunction (LVEF &lt; 50%)

          -  Clinically significant coronary artery disease, valvular heart disease, significant
             arrhythmias, or conduction delays.

          -  Uncontrolled arterial hypertension defined as systolic blood pressure &gt; 170 mm Hg

          -  Treatment with ACEI, ARB or beta-blocker within the last 4 weeks prior to study start

          -  Intolerance to ACEI, ARB or beta-blocker

          -  Uncontrolled concomitant serious illness

          -  Pregnancy or breastfeeding

          -  Active abuse of drugs or alcohol

          -  Suspected poor compliance

          -  Inability to tolerate the MRI scanning protocol
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stein Vaaler</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Akershus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Akershus University Hospital</name>
      <address>
        <city>LÃ¸renskog</city>
        <zip>1478</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2011</study_first_submitted>
  <study_first_submitted_qc>September 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2011</study_first_posted>
  <last_update_submitted>October 21, 2014</last_update_submitted>
  <last_update_submitted_qc>October 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Akershus</investigator_affiliation>
    <investigator_full_name>Torbjorn Omland</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Anthracyclines</keyword>
  <keyword>Trastuzumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

